Connor Clark & Lunn Investment Management Ltd. Buys 82,988 Shares of MacroGenics, Inc. (NASDAQ:MGNX)

Connor Clark & Lunn Investment Management Ltd. grew its stake in MacroGenics, Inc. (NASDAQ:MGNX) by 12.5% during the fourth quarter, Holdings Channel reports. The firm owned 744,902 shares of the biopharmaceutical company’s stock after purchasing an additional 82,988 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in MacroGenics were worth $2,421,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of MGNX. XTX Topco Ltd bought a new position in shares of MacroGenics in the third quarter valued at approximately $37,000. Sanders Morris Harris LLC bought a new position in shares of MacroGenics in the fourth quarter valued at approximately $40,000. Intech Investment Management LLC bought a new position in shares of MacroGenics in the third quarter valued at approximately $68,000. XML Financial LLC lifted its holdings in shares of MacroGenics by 31.6% in the fourth quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 5,569 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of MacroGenics by 104.5% in the fourth quarter. SG Americas Securities LLC now owns 34,399 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 17,577 shares in the last quarter. Institutional investors own 96.89% of the company’s stock.

MacroGenics Trading Down 6.0 %

Shares of MacroGenics stock opened at $2.05 on Wednesday. The business’s fifty day simple moving average is $2.73 and its 200 day simple moving average is $3.24. The firm has a market capitalization of $128.66 million, a P/E ratio of -1.30 and a beta of 2.12. MacroGenics, Inc. has a 12 month low of $2.04 and a 12 month high of $19.54.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.